Bulkamid Urethral Bulking System
BOSTON SCIENTIFIC CORPORATION · Decision date Jul 1, 2026
What did the FDA decide?
FDA records P170023/S024 as a supplement to PMA P170023, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 1, 2026.
FDA approval order statement
Manufacturing the Bulkamid Hydrogel in new cleanrooms at the existing manufacturing site.
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Gastroenterology, Urology
- Decision date
- Jul 1, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P170023/S024
- Regulatory pathway
- PMA supplement
- Applicant
- BOSTON SCIENTIFIC CORPORATION
- Product code
- LNM
- Decision code
- OK30
- Decision date
- Jul 1, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: AGENT, BULKING, INJECTABLE FOR GASTRO-UROLOGY USE.
- Applicant
- Boston Scientific Corporation
- Product code
- LNM
- FDA device class
- 3
Review the original FDA PMA listing for the original approval scope and linked supplements.
FDA decision timeline
P170023/S023 · Related supplement
Bulkamid Urethral Bulking System
P170023/S024 received
Application receipt date recorded by FDA.
P170023/S024 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P170023. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170023
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Bulkamid Urethral Bulking SystemP170023/S023 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Jan 2, 2026 | FDA |
Explore the linked device profile
Other records with product code LNM
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Merz North America, Inc. | PMA supplement | Jun 26, 2026 | FDA | |
| Merz North America, Inc. | PMA supplement | May 14, 2026 | FDA | |
COAPTITE Injectable ImplantP040047/S081 | Merz North America, Inc. | PMA supplement | Mar 18, 2026 | FDA |
Durasphere Injectable Bulking AgentP980053/S021 | Carbon Medical Technologies, Inc. | PMA supplement | Mar 13, 2026 | FDA |
COAPTITEP040047/S080 | Merz North America, Inc. | PMA supplement | Jan 13, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Boston Scientific Corporation
- Headquarters
- Not reported
- Brand website
- bostonscientific.com
- FDA applicant address
- 100 Boston Scientfic Way, Marlborough, MA, 01752
Sources and methodology
- Original FDA record: P170023/S024
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


